Keros Therapeutics Advances Rinvatercept in ALS Collaboration

Keros Therapeutics ( (KROS) ) has shared an update.

On March 9, 2026, Keros Therapeutics announced it has entered into an agreement with Massachusetts General Hospital to design a Phase 2 clinical trial of its lead drug candidate rinvatercept for amyotrophic lateral sclerosis within the Healey ALS MyMatch program, a biomarker-driven initiative led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The ALS MyMatch network, which includes several high-enrolling U.S. research centers, uses genetic and biofluid markers to match ALS patient subgroups to experimental therapies in a series of early-stage Phase 1b/2a trials.

Keros also reported on March 9, 2026 that it presented additional data from its Phase 1 clinical trial of rinvatercept in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting continued clinical progress for the program. Together, the collaboration with the Healey & AMG Center and the new Phase 1 data mark a significant step in advancing rinvatercept’s development in ALS and reinforce Keros’s positioning as an emerging player in muscle and neuromuscular disease therapeutics.

The most recent analyst rating on (KROS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Spark’s Take on KROS Stock

According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.

The score is driven primarily by improved 2025 financial performance (profitability and strong free cash flow with low leverage), tempered by high historical volatility in revenue/earnings. Technicals are a major offset, with the stock below all key moving averages and bearish momentum indicators. Valuation is supportive due to a low P/E, while recent corporate updates are modestly positive but not clearly catalytic on their own.

To see Spark’s full report on KROS stock, click here.

More about Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel protein therapeutics targeting dysfunctional signaling of the TGF-ß family of proteins, which regulate growth, repair and maintenance of tissues such as skeletal muscle, bone and blood. Its lead candidate rinvatercept is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndrome and myelofibrosis patients.

The company aims to deliver potentially disease-modifying treatments by leveraging its expertise in TGF-ß biology to address serious disorders with high unmet medical need across muscle, bone and hematologic indications. Traded on Nasdaq under the ticker KROS, Keros focuses on advancing its pipeline through clinical development collaborations with leading academic and research centers.

Average Trading Volume: 401,045

Technical Sentiment Signal: Sell

Current Market Cap: $222.8M

See more insights into KROS stock on TipRanks’ Stock Analysis page.